Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$5.05
+4.3%
$4.80
$3.42
$6.91
$285.07M1.911.86 million shs931,363 shs
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
$2.78
-10.0%
$2.66
$1.47
$17.31
$67.92M2.99214,384 shs94,042 shs
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
$3.87
-1.5%
$3.59
$1.61
$9.50
$320.36M0.911.09 million shs855,271 shs
Ocugen, Inc. stock logo
OCGN
Ocugen
$1.03
$1.03
$0.52
$1.29
$301.07M4.164.28 million shs1.63 million shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
-1.43%-10.70%+8.04%-18.66%-10.54%
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
-14.40%-1.90%+11.96%+48.56%-74.29%
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
-0.25%+8.56%+9.78%+35.05%-51.18%
Ocugen, Inc. stock logo
OCGN
Ocugen
0.00%+0.98%+3.17%-8.85%-9.65%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$5.05
+4.3%
$4.80
$3.42
$6.91
$285.07M1.911.86 million shs931,363 shs
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
$2.78
-10.0%
$2.66
$1.47
$17.31
$67.92M2.99214,384 shs94,042 shs
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
$3.87
-1.5%
$3.59
$1.61
$9.50
$320.36M0.911.09 million shs855,271 shs
Ocugen, Inc. stock logo
OCGN
Ocugen
$1.03
$1.03
$0.52
$1.29
$301.07M4.164.28 million shs1.63 million shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
-1.43%-10.70%+8.04%-18.66%-10.54%
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
-14.40%-1.90%+11.96%+48.56%-74.29%
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
-0.25%+8.56%+9.78%+35.05%-51.18%
Ocugen, Inc. stock logo
OCGN
Ocugen
0.00%+0.98%+3.17%-8.85%-9.65%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
3.00
BuyN/AN/A
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
3.00
Buy$17.00511.51% Upside
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
3.00
Buy$18.43376.19% Upside
Ocugen, Inc. stock logo
OCGN
Ocugen
3.00
Buy$6.00482.52% Upside

Current Analyst Ratings Breakdown

Latest ARTV, ACB, LRMR, and OCGN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/15/2025
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
JMP Securities
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetMarket Outperform$22.00 ➝ $18.00
8/8/2025
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong Sell
8/4/2025
Ocugen, Inc. stock logo
OCGN
Ocugen
Chardan Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$7.00
6/24/2025
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
6/24/2025
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$17.00 ➝ $15.00
6/24/2025
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$26.00
6/24/2025
Ocugen, Inc. stock logo
OCGN
Ocugen
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$7.00
6/24/2025
Ocugen, Inc. stock logo
OCGN
Ocugen
Chardan Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$7.00
6/11/2025
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeBuy$12.00
(Data available from 9/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$246.72M1.16$0.63 per share8.03$7.78 per share0.65
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
$250K271.66N/AN/A$7.68 per share0.36
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
N/AN/AN/AN/A$2.69 per shareN/A
Ocugen, Inc. stock logo
OCGN
Ocugen
$4.05M74.34N/AN/A$0.10 per share10.30
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$1.63M-$0.19N/A11.48N/A-5.66%-1.49%-1.06%11/5/2025 (Estimated)
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
-$65.37MN/A0.00N/AN/AN/A-42.60%-37.76%11/11/2025 (Estimated)
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
-$80.60M-$1.56N/AN/AN/AN/A-62.92%-53.98%10/29/2025 (Estimated)
Ocugen, Inc. stock logo
OCGN
Ocugen
-$54.05M-$0.20N/AN/AN/A-1,197.71%-255.25%-86.79%11/13/2025 (Estimated)

Latest ARTV, ACB, LRMR, and OCGN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
-$0.47-$0.41+$0.06-$0.41N/AN/A
8/6/2025Q1 2026
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$0.18-$0.19-$0.37-$0.20$96.83 million$71.98 million
8/6/2025Q2 2025
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
-$0.84-$0.87-$0.03-$0.87N/AN/A
8/1/2025Q2 2025
Ocugen, Inc. stock logo
OCGN
Ocugen
-$0.06-$0.05+$0.01-$0.05$0.35 million$1.37 million
6/18/2025Q4 2025
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$0.11$0.07-$0.04-$0.24$88.85 million$63.34 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
N/AN/AN/AN/AN/A
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
N/AN/AN/AN/AN/A
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
N/AN/AN/AN/AN/A
Ocugen, Inc. stock logo
OCGN
Ocugen
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.06
2.97
1.51
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
N/A
13.84
13.84
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
N/A
5.46
5.46
Ocugen, Inc. stock logo
OCGN
Ocugen
9.18
1.83
1.83

Institutional Ownership

CompanyInstitutional Ownership
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
47.63%
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
N/A
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
91.92%
Ocugen, Inc. stock logo
OCGN
Ocugen
10.27%

Insider Ownership

CompanyInsider Ownership
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.01%
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
21.40%
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
4.50%
Ocugen, Inc. stock logo
OCGN
Ocugen
4.29%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
1,13056.45 million56.45 millionOptionable
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
8124.43 million19.20 millionN/A
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
3082.78 million79.05 millionOptionable
Ocugen, Inc. stock logo
OCGN
Ocugen
80292.30 million279.77 millionOptionable

Recent News About These Companies

Nuveen LLC Takes Position in Ocugen, Inc. $OCGN
GMT Capital Corp Grows Position in Ocugen, Inc. $OCGN
Ocugen (NASDAQ:OCGN) Stock Price Up 3% - Here's Why
Ocugen Inc
Ocugen Reports Progress in Gene Therapy Trials

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aurora Cannabis stock logo

Aurora Cannabis NASDAQ:ACB

$5.05 +0.21 (+4.34%)
Closing price 04:00 PM Eastern
Extended Trading
$5.11 +0.06 (+1.09%)
As of 06:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Aurora Cannabis Inc., together with its subsidiaries, produces, distributes, and sells cannabis and cannabis-derivative products in Canada and internationally. It operates through three segments: Canadian Cannabis, European Cannabis, and Plant Propagation. The company produces, distributes, and sells medical and consumer cannabis products in Canada. It is also involved in the distribution of wholesale medical cannabis in the European Union (EU); distribution of wholesale medical cannabis in various international markets, including Australia, the Caribbean, South America, and Israel; supply of propagated vegetables and ornamental plants in North America; and distribution and sale of hemp-derived cannabidiol (CBD) products. In addition, the company cultivates and sells dried cannabis, cannabis oils, capsules, edible cannabis, cannabis extracts, and soft gels, which are ingested in various ways, including smoking, vaporizing, and consumption in the form of oil, capsules, edibles, and extracts; and provides dried flowers, vapes, dried milled strains, strain-specific extracts, strain specific cannabis oils, and concentrates. Further, it offers recreational cannabis products, such as flowers, vapes, ingestibles, concentrates, extracts, and CBD products; and patient counseling and outreach services. The company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard, as well as CBD brands, Reliva and KG7; and medical cannabis brands include MedReleaf, CanniMed, Aurora, Whistler Medical Marijuana Co, Pedanios, Bidiol, and CraftPlant. Aurora Cannabis Inc. is headquartered in Edmonton, Canada.

Artiva Biotherapeutics stock logo

Artiva Biotherapeutics NASDAQ:ARTV

$2.78 -0.31 (-10.03%)
Closing price 04:00 PM Eastern
Extended Trading
$2.86 +0.09 (+3.06%)
As of 05:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.

Larimar Therapeutics stock logo

Larimar Therapeutics NASDAQ:LRMR

$3.87 -0.06 (-1.53%)
Closing price 04:00 PM Eastern
Extended Trading
$3.86 -0.01 (-0.26%)
As of 06:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.

Ocugen stock logo

Ocugen NASDAQ:OCGN

$1.03 0.00 (0.00%)
Closing price 04:00 PM Eastern
Extended Trading
$1.02 -0.01 (-0.49%)
As of 06:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.